Volume 88, Issue 2 pp. 209-216
Cancer Genetics

Variant estrogen receptor α mRNAs in human breast cancer specimens

Shanez Y. Anandappa

Shanez Y. Anandappa

Molecular Medicine Research Group, School of Biological Sciences, University of Liverpool, Liverpool, UK

Search for more papers by this author
Ross Sibson

Ross Sibson

J.K. Douglas Research Laboratories, Clatterbridge Cancer Research Trust, Clatterbridge Hospital, Clatterbridge, Wirral, UK

Search for more papers by this author
Angela Platt-Higgins

Angela Platt-Higgins

Molecular Medicine Research Group, School of Biological Sciences, University of Liverpool, Liverpool, UK

Search for more papers by this author
John H.R. Winstanley

John H.R. Winstanley

Molecular Medicine Research Group, School of Biological Sciences, University of Liverpool, Liverpool, UK

Search for more papers by this author
Philip S. Rudland

Philip S. Rudland

Molecular Medicine Research Group, School of Biological Sciences, University of Liverpool, Liverpool, UK

Search for more papers by this author
Roger Barraclough

Corresponding Author

Roger Barraclough

Molecular Medicine Research Group, School of Biological Sciences, University of Liverpool, Liverpool, UK

Life Sciences Building, University of Liverpool, P.O. Box 147, Liverpool L69 7ZB, UK. Fax: +44-151 794 4327Search for more papers by this author

Abstract

A panel of human breast cancer specimens was examined for single base change mutations by DNA sequencing and for larger deletions using a PCR-based assay. In the cancer specimens examined, no sequencing variants were detected other than a previously characterized polymorphism. Although most of the specimens contained estrogen receptor (ER) variants at a low level, 2 of 118 specimens exhibited variants which, after amplification, constituted most of the amplified ER cDNA. One specimen contained a single variant form, and there was little evidence of the wild-type ER mRNA by PCR, Northern blotting or immunocytochemistry. The second specimen, despite the presence of a normal-sized mRNA by Northern blotting and normal immunocytochemical staining for ER, contained at least 5 different variant forms as well as the wild-type ER. All but 1 of the variant forms were processing variants, and 3 of these processing variants have not been described before. One variant, although lacking exons 2–4, has break points in exons 1 and 5 that do not correspond to intron–exon boundaries. This variant might reflect more widespread damage to the genome in this breast cancer specimen. The low level of occurrence of variants suggests that ER variant forms, at least in the coding region, do not contribute generally to the progression of breast cancer. Int. J. Cancer 88:209–216, 2000. © 2000 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.